Research Progress of Immuno-Inhibitory Receptors in Gynecological Cervical Cancer
The mortality rate of cervical cancer is the highest among female malignant tumors and seriously threatens women's lives and health. Persistent high-risk human papillomavirus (HPV) infection is the leading cause of cervical cancer, which provides the basis for immunotherapy. In recent years, ow...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2023-11-01
|
| Series: | Technology in Cancer Research & Treatment |
| Online Access: | https://doi.org/10.1177/15330338231208846 |
| _version_ | 1827776821987377152 |
|---|---|
| author | Yang Li MS Fangrong Shen MD Qingqing Tan MD Youguo Chen MD Yanzheng Gu MD |
| author_facet | Yang Li MS Fangrong Shen MD Qingqing Tan MD Youguo Chen MD Yanzheng Gu MD |
| author_sort | Yang Li MS |
| collection | DOAJ |
| description | The mortality rate of cervical cancer is the highest among female malignant tumors and seriously threatens women's lives and health. Persistent high-risk human papillomavirus (HPV) infection is the leading cause of cervical cancer, which provides the basis for immunotherapy. In recent years, owing to progress in targeted therapy and immunotherapy, the survival time of patients with cervical cancer has been significantly extended. However, effective treatments for advanced, recurrent, and metastatic cancers are lacking. “Tumor immunotherapy” has been described as a viable option for tumor therapy but the efficacy of immunotherapy for cervical cancer has only been demonstrated in phase I or II clinical trials. Immune checkpoint inhibitors (ICIs) have shown promising clinical results particularly for treating recurrent and advanced cervical cancer, however, they remain inadequate in some patients. Immune checkpoint is the target of immunotherapy. Therefore, the identification of novel therapeutic targets is essential. In this paper, the structure, expression, function, biological effect of immune inhibitory receptors (IRs) and related clinical studies were reviewed, in order to further explore the application potential of these immune checkpoints and apply them to the future clinical treatment of cervical cancer. |
| first_indexed | 2024-03-11T14:10:02Z |
| format | Article |
| id | doaj.art-3dc205a6e8c44750a5b07f5d48c72479 |
| institution | Directory Open Access Journal |
| issn | 1533-0338 |
| language | English |
| last_indexed | 2024-03-11T14:10:02Z |
| publishDate | 2023-11-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Technology in Cancer Research & Treatment |
| spelling | doaj.art-3dc205a6e8c44750a5b07f5d48c724792023-11-02T00:33:21ZengSAGE PublishingTechnology in Cancer Research & Treatment1533-03382023-11-012210.1177/15330338231208846Research Progress of Immuno-Inhibitory Receptors in Gynecological Cervical CancerYang Li MS0Fangrong Shen MD1Qingqing Tan MD2Youguo Chen MD3Yanzheng Gu MD4 Department of Gynecology and obstetrics, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China Department of Gynecology and obstetrics, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China Department of Gynecological Oncology, The Affiliated Changzhou Maternal and Child Health Care Hospital of Nanjing Medical University, Changzhou, Jiangsu, China Department of Gynecology and obstetrics, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China Jiangsu Institute of Clinical Immunology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, ChinaThe mortality rate of cervical cancer is the highest among female malignant tumors and seriously threatens women's lives and health. Persistent high-risk human papillomavirus (HPV) infection is the leading cause of cervical cancer, which provides the basis for immunotherapy. In recent years, owing to progress in targeted therapy and immunotherapy, the survival time of patients with cervical cancer has been significantly extended. However, effective treatments for advanced, recurrent, and metastatic cancers are lacking. “Tumor immunotherapy” has been described as a viable option for tumor therapy but the efficacy of immunotherapy for cervical cancer has only been demonstrated in phase I or II clinical trials. Immune checkpoint inhibitors (ICIs) have shown promising clinical results particularly for treating recurrent and advanced cervical cancer, however, they remain inadequate in some patients. Immune checkpoint is the target of immunotherapy. Therefore, the identification of novel therapeutic targets is essential. In this paper, the structure, expression, function, biological effect of immune inhibitory receptors (IRs) and related clinical studies were reviewed, in order to further explore the application potential of these immune checkpoints and apply them to the future clinical treatment of cervical cancer.https://doi.org/10.1177/15330338231208846 |
| spellingShingle | Yang Li MS Fangrong Shen MD Qingqing Tan MD Youguo Chen MD Yanzheng Gu MD Research Progress of Immuno-Inhibitory Receptors in Gynecological Cervical Cancer Technology in Cancer Research & Treatment |
| title | Research Progress of Immuno-Inhibitory Receptors in Gynecological Cervical Cancer |
| title_full | Research Progress of Immuno-Inhibitory Receptors in Gynecological Cervical Cancer |
| title_fullStr | Research Progress of Immuno-Inhibitory Receptors in Gynecological Cervical Cancer |
| title_full_unstemmed | Research Progress of Immuno-Inhibitory Receptors in Gynecological Cervical Cancer |
| title_short | Research Progress of Immuno-Inhibitory Receptors in Gynecological Cervical Cancer |
| title_sort | research progress of immuno inhibitory receptors in gynecological cervical cancer |
| url | https://doi.org/10.1177/15330338231208846 |
| work_keys_str_mv | AT yanglims researchprogressofimmunoinhibitoryreceptorsingynecologicalcervicalcancer AT fangrongshenmd researchprogressofimmunoinhibitoryreceptorsingynecologicalcervicalcancer AT qingqingtanmd researchprogressofimmunoinhibitoryreceptorsingynecologicalcervicalcancer AT youguochenmd researchprogressofimmunoinhibitoryreceptorsingynecologicalcervicalcancer AT yanzhenggumd researchprogressofimmunoinhibitoryreceptorsingynecologicalcervicalcancer |